Uncategorized

Sirnaomics Ltd., a leading biopharmaceutical company in discovery and development of RNAi therapeutics, has announced its interim results for the six months ended 30 June 2023.

Sirnaomics Ltd. announced the Group has completed all dosing regimens for its Phase I study of STP707 for the treatment of multiple solid tumors in patients with various types of late-stage cancers who did not respond to multiple rounds of other oncology treatments.

Syngenta Group announced financial results for the first half and the second quarter of 2023.

Inventiva, a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with non-alcoholic steatohepatitis and other diseases with significant unmet medical needs, announced an approximately €35.7 million financing.

Verona Pharma plc, announces effective September 1, 2023, Ms. Christina Ackermann will join the board as a Non-Executive Director.

La inteligencia animal ha sido durante mucho tiempo un enigma fascinante para la ciencia. Desde las asombrosas capacidades cognitivas de los delfines hasta la sorprendente memoria de los elefantes, los animales han demostrado habilidades mentales que desafían las percepciones tradicionales. …

En un mundo cada vez más interconectado y tecnológicamente avanzado, la ciencia y la tecnología no se detienen, y la fotónica se erige como una de las disciplinas más prometedoras de la era moderna. La fotónica es una rama de la ciencia que se centra en el e …

As the new CEO of LimmaTech Biologics, Haas’ IP and legal background sets him apart to lead the charge for the team’s bacterial vaccine pipeline.

However, a lack of regulatory harmonization risks are undermining the effective implementation of these technology-driven approaches.

The current workforce lacks the skills to move these biological treatments through the regulatory and production pipeline, a new report finds.